BRIEF—Tonix buys two migraine meds from Upsher-Smith

Tonix Pharmaceuticals is to buy two marketed acute migraine products from Upsher-Smith Laboratories - Zembrace SymTouch (sumatriptan) and Tosymra (sumatriptan).

Togeher, these products generated sales of around $23 million last year.

Tonix will pay $12 million right away and an additional $3 million by March 2024, as well as $10 million in cash at closing to acquire inventory.

Chief medical officer Gregory Sullivan said: “For certain patients who present to emergency rooms, Zembrace SymTouch and Tosymra provide staff a straightforward acute treatment option.”

“Additionally, because both of these products bypass the gastrointestinal tract, they have the potential to provide a treatment option for migraines complicated by severe nausea and vomiting,” he added.